The Clorox Company (CLX)
NEUTRALFundamental
47
Kurs
$104.43
Marktkapitalisierung
$12.98B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Clorox makes household staples sold under well-known names: bleach and cleaning sprays under its own Clorox brand, trash bags under Glad, charcoal under Kingsford, and personal-care and health products including Burt's Bees. It manufactures most of what it sells, ships it to large retailers, and relies on repeat, habitual purchases rather than one-off sales — a household restocks bleach or trash bags on a predictable cycle regardless of the wider economy.
Wie das Geld verdient wird
Revenue comes from selling packaged goods to a concentrated set of large retailers, who then resell to shoppers. Margins depend on the cost of raw materials such as resin and chemicals, on manufacturing efficiency, and on holding shelf space and brand loyalty against cheaper private-label alternatives that retailers sell alongside Clorox's own products. The company reports results across four segments split by product category and by U.S. versus international markets.
Umsatz nach Segment
Cleaning and disinfecting products under Clorox, plus water filtration under Brita and vitamins under Natural Vitality.
Trash bags under Glad, cat litter under Fresh Step and Scoop Away, and charcoal under Kingsford.
Food products including Hidden Valley dressings, and personal care through Burt's Bees.
The same core product categories sold outside the United States, mainly in Latin America and Canada.
Wettbewerbsvorteil
Marke · SchmalNames like Clorox, Glad and Kingsford have been the default choice on U.S. shelves for generations, which lets the company hold shelf space and charge more than an unbranded equivalent. The advantage is narrow: retailer store brands compete directly in nearly every category, and a large retailer with real pricing leverage can push back hard on Clorox's terms.
Was die Nachfrage antreibt
DefensivCleaning products, trash bags and personal care items are routine, non-discretionary household purchases that people keep buying in a downturn, which makes volume relatively stable across the economic cycle. The bigger swings in results tend to come from input-cost inflation and from consumers trading down to private label when money is tight, not from skipping the purchase altogether.
Wichtigste Risiken
- Retailer concentration — With Walmart alone worth nearly 27% of net sales, large retailers have the leverage to demand better pricing terms or to favour their own private-label products over Clorox's brands.
- Input cost and supply chain disruption — Volatile commodity, packaging, labour, energy and logistics costs, along with the risk of supply disruption from conflicts such as those in Ukraine, the Middle East, or tensions between China and Taiwan, can raise costs faster than prices can be adjusted.
- Cybersecurity — The company depends heavily on information technology systems and has already suffered a major cyberattack, in August 2023, that disrupted operations; a repeat incident could again halt production and shipments.
- Private-label competition — Store-brand alternatives, often priced well below Clorox's products, compete in nearly every category the company sells in, forcing continued spending on marketing and innovation to defend market share.
Kundenkonzentration
Die größten Kunden machen 27 % des Umsatzes aus
Walmart and its affiliates accounted for nearly 27% of net sales in fiscal 2025, giving a single retailer significant leverage over shelf placement, promotional terms and pricing.
Die Argumente dafür
Buyers argue that Clorox's brands are habit-forming staples that hold shelf space no private label can fully dislodge, and that the company's cost-savings programme and full recovery from the 2023 cyberattack position it to grow margins even on roughly flat sales.
Die Argumente dagegen
Sellers worry that with Walmart alone worth over a quarter of sales, Clorox has limited room to push back on retailer demands, and that persistent private-label competition plus input-cost inflation could keep squeezing volumes and margins at the same time.
Written by the editors, published on 18. August 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$6.76B
Letzte 12 Monate (bis 31.3.2026)
Nettogewinn
$756M
Letzte 12 Monate (bis 31.3.2026)
Freier Cashflow
$761M
Gesamtes Eigenkapital
$321M
Gesamtverbindlichkeiten
$5.08B
Current Ratio
0.84
Zinsdeckungsgrad
-
Schulden/EBITDA
3.94
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$110.05
Aktueller Kurs
$104.43
Sicherheitsmarge
+5.1%
Innerer-Wert-Spanne
$71.53 - $148.56
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
17.40
ROE
252.3%
P/B-Verhältnis
40.43
P/FCF
34.10
Bruttomarge
43.8%
ROIC
-
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
-
WACC
6.3%
ROIC − WACC
-
Fundamentalanalyse-Kriterien
Bestanden (11)
- EPS shows upward trend
- Gross Margin 43.8%
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 181.1%
- Earnings Quality (OCF/NI) 0.76
- Share Dilution -0.2%
- Net Margin Trend 11.2% vs 9.9%
- Piotroski F-Score 8/9
Nicht bestanden (12)
- EPS CAGR 4.22%
- Price CAGR -1.17%
- P/FCF 34.10
- P/B Ratio 40.43
- Debt/Equity ratio
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly valued)
- Revenue Growth 5Y -1.8%
- Analyst Consensus 4% Buy
- Earnings Surprise avg 1.8%
Nicht verfügbar (5)
- ROIC NaN%
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Starke finanzielle Gesundheit
Gewinnqualität
Mittel: Gewisse Differenz zwischen Gewinn und Cashflow
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Ms. Linda J. Rendle | CEO & Chairman | 47 |
| Mr. Luc Bellet | Executive VP & CFO | 46 |
| Ms. Nina Barton | Executive VP and Chief Growth & Strategy Officer | 51 |
| Ms. Laura E. Peck | VP, Chief Accounting Officer & Corporate Controller | 48 |
| Ms. Kirsten M. Marriner | Executive VP & Chief Administrative Officer | 52 |
| Ms. Lisah Burhan | Vice President of Investor Relations | - |
Prüfungsrisiko
7
Vorstandsrisiko
3
Vergütungsrisiko
6
Aktionärsrechterisiko
8
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for CLX, sourced from Markets Gazette.
- 22d agoPOSITIVEClorox Expects Full-Year Sales Boost From Purell Deal
The Clorox Company announced fiscal fourth-quarter earnings that surpassed analyst forecasts, signaling resilience despite challenges. While sales volumes were down and the recent acquisition of GOJO Industries, the maker of Purell, incurred additional logistics costs, the overall financial performance indicates effective management. The company anticipates a full-year sales boost stemming from the Purell integration, suggesting a positive outlook for future revenue streams. Investors will be watching the successful integration of GOJO and its impact on Clorox's market position and profitability in the coming quarters.
via Markets Gazette